Preliminary results of a phase I/II study of the humanized anti-CD20 antibody IMMU-106 (hA20) in patients with relapsed non-Hodgkin lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL LYMPHOMA & MYELOMA | 2007年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339 / 341
页数：3
相关论文
共 50 条
  • [41] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Ely, S
    Furman, RR
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Cesano, A
    Goldenberg, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3051 - 3059
  • [42] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    [J]. BLOOD, 2002, 100 (11) : 358A - 358A
  • [43] Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody (vol 113, pg 1062, 2009)
    Goldenberg
    [J]. BLOOD, 2009, 113 (21) : 5368 - 5368
  • [44] Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    Piro, LD
    White, CA
    Grillo-López, AJ
    Janakiraman, N
    Saven, A
    Beck, TM
    Varns, C
    Shuey, S
    Czuczman, M
    Lynch, JW
    Kolitz, JE
    Jain, V
    [J]. ANNALS OF ONCOLOGY, 1999, 10 (06) : 655 - 661
  • [45] Anti-CD20 monoclonal antibody (rituximab) associated to mine and autotransplantation in patients with relapsed or primary refractary follicular or transformed follicular non-Hodgkin lymphoma (NHL).
    Solano, C
    Gutiérrez, AM
    Benet, I
    Marugán, I
    Tormo, M
    Terol, MJ
    Prósper, F
    García-Conde, J
    [J]. BLOOD, 1999, 94 (10) : 406B - 406B
  • [46] Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
    Sharkey, Robert M.
    Karacay, Habibe
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, William J.
    Chang, Chien-Hsing
    Goldenberg, David M.
    [J]. CANCER RESEARCH, 2008, 68 (13) : 5282 - 5290
  • [47] IDEC-Y2B8 (90)yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a Phase I/II trial.
    Witzig, T
    Wiseman, C
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanoulides, C
    Royston, I
    Parker, E
    Chinn, P
    GrilloLopez, A
    [J]. BLOOD, 1997, 90 (10) : 2606 - 2606
  • [48] HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.
    Hagenbeek, A
    Plesner, T
    Johnson, P
    Pedersen, L
    Walewski, J
    Hellmann, A
    Link, B
    Robak, T
    Wojtukiewicz, M
    Pfreundschuh, M
    Kneba, M
    Engert, A
    Sonneveld, P
    Petersen, J
    Radford, J
    [J]. BLOOD, 2005, 106 (11) : 270B - 270B
  • [49] Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results
    Tomblyn, Michael B.
    Witzig, Thomas E.
    Himelstein, Andrew L.
    Elstrom, Rebecca
    Kio, Ebenezer A.
    Sharkey, Robert M.
    Rojo, Jonathan
    Wegener, William
    Goldenberg, David M.
    [J]. BLOOD, 2012, 120 (21)
  • [50] Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Shi, Yuankai
    Yang, Jianliang
    Song, Yongping
    Zhou, Keshu
    Li, Zhiming
    Zhang, Mingzhi
    Jing, Hongmei
    Wang, Zhen
    Yu, Li
    Lu, Qiying
    Gan, Frank
    Tian, Wenzhi
    [J]. CANCER RESEARCH, 2024, 84 (07)
12345